Early functional outcome after IV rTPA administration in Egyptian acute ischemic stroke patients
Tóm tắt
Intravenous thrombolysis has become a standard practice in eligible patients with acute ischemic stroke (AIS). Functional outcome after AIS is a major concern for patients, families, and neurologists. Identifying factors affecting the early functional outcome and the effect of IV rTPA in Egyptian AIS patients is crucial to address concerns and queries. Compare functional outcome between AIS patients treated with and without IV rTPA and to study clinical predictors of outcome. This study was performed on AIS within 24 h of symptom onset. Patients were dichotomized into group I, patients who received IV rTPA, and group II, patients who had contraindication to it. Patients were assessed with NIHSS and mRS at 3 months. The functional outcome was studied in relation to risk factors, TOAST classification, OSCP classification, and NIHSS severity. In mild stroke: group I showed better 7-day NIHSS and 3-month mRs, when compared to group II, (P 0.002, 0.089 respectively). In group I, 68.6% of patients with total anterior circulation syndrome (TACS) had unfavorable outcome (P = 0.004). Those with lacunar syndrome, 78.6% had favorable outcome (P = 0.0162). In group I, there was a positive correlation between 3-month mRs and age, NIHSS on admission, and NIHSS at 7 days (P 0.017, < 0.001, < 0.001, respectively). Age and NIHSS at admission were correlated with poor outcome at 3 months in the IV rTPA group. Better functional outcome was observed in thrombolysed patients in groups with mild stroke severity. The study showed that patients with TACS had the most unfavorable outcome, while lacunar infarction patients had the most favorable outcome.
Tài liệu tham khảo
The national institute of neurological disorders and stroke rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.
Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, et al. Scientific statement for inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from American heart association/ American stroke association. Stroke. 2016;47:581–641.
Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–70.
Bhardwaj A, Sharma G, Raina SK, Sharma A, Angra M. Advanced age and higher National Institutes of Health Stroke Scale Score as predictors of poor outcome in ischemic stroke patients treated with alteplase: a study from a tertiary care centre in rural North-west India. J Neurosci Rural Pract. 2017;8(2):236–40.
Spaander FH, Zinkstok SM, Baharoglu IM, H G, A P, Traenka C, et al. Sex differences and functional outcome after intravenous thrombolysis. Stroke. 2017;48:699–703.
Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, and the Multicentre tPA Stroke Survey Group, et al. Predictors of good outcome after intravenous rt-PA for acute ischemic stroke: The multi-centre tPA acute stroke survey. Neurology. 2001;57:474–80.
Vogt G, Laage R, Shuaib A, Schneider A, VISTA Collaboration. Initial lesion volume is an independent predictor of clinical stroke outcome at day 90: an analysis of the Virtual International Stroke Trials Archive (VISTA) database. Stroke. 2012;43:1266–72.
Yang Y, Wang A, Zhao X, Wang C, Liu L, Zheng H, et al. The Oxfordshire Community Stroke Project classification system predicts clinical outcomes following intravenous thrombolysis: a prospective cohort study. Ther Clin Risk Manag. 2016;12:1049–56.
Fuentes B, Martínez-Sánchez P, Alonso D, Egido J, Reig-Roselló G, Díaz-Otero F, et al. Madrid Stroke Network. Efficacy of intravenous thrombolysis according to stroke subtypes: the Madrid Stroke Network data. Eur J Neurol. 2012;19:1568–74.
Mustanoja S, Meretoja A, Putaala J, Viitanen V, Curtze S, Atula S, et al. Helsinki Stroke Thrombolysis Registry Group. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive sub-type analysis. Stroke. 2011;42:102–6.
Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–7.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST:Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337(8756):1521–6.
Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet. 2007;369:293–8.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics update a report from the American Heart Association. Circulation. 2016;133(4):e38–48.
Muchada M, Rodriguez-Luna D, Pagola J, Flores A, Sanjuan E, Meler P, et al. Impact of time to treatment on tissue-type plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2014;45:2734–8.